Alligator Bioscience AB (publ) (STO:ATORX)

Market Cap	7.98M -95.7%
Revenue (ttm)	681.00K -98.4%
Net Income	-77.70M
EPS	-0.24
Shares Out	628.11M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,811,585
Open	0.0133
Previous Close	0.0132
Day's Range	0.0126 - 0.0134
52-Week Range	0.0126 - 4.4000
Beta	1.17
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 22, 2026

About Alligator Bioscience AB

Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Belgium. The company develops Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 3 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage for the treatment of solid metastatic tumors. It also offers ALG.APV-52...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 11
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ATORX

Financial Performance

In 2025, Alligator Bioscience AB's revenue was 839,000, a decrease of -98.55% compared to the previous year's 57.72 million. Losses were -51.35 million, -78.05% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 19, 2026

Data Sources Report a data error